Epstein-Barr Virus and Cancer Risks
EBVCR
Prospective Cohort Study on Epstein-Barr Virus Antibody and Cancer Risks
1 other identifier
observational
100,000
1 country
2
Brief Summary
The goal of this prospective cohort study is to investigate the associations between Epstein-Barr Virus (EBV) antibody levels and the risk of overall and site-specific cancer types in Southern China. The main questions it aims to answer are: Question 1: In addition to the established EBV-associated cancer types, such as lymphomas, nasopharyngeal carcinoma, and stomach cancer, whether EBV is associated with other cancer types? Question 2: What's the cancer burden attributed to EBV in Southern China?
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2008
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2008
CompletedFirst Submitted
Initial submission to the registry
December 29, 2023
CompletedFirst Posted
Study publicly available on registry
January 12, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2030
ExpectedJanuary 12, 2024
January 1, 2024
16.4 years
December 29, 2023
January 11, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cancer incidence
The primary outcome of the study was the diagnosis of any type of cancer. The cancer type for each participant was defined as their initial and primary cancer diagnosis.
10 years
Secondary Outcomes (1)
All-cause mortality
10 years
Study Arms (2)
Zhongshan cohort, Guangdong, China
30-59 years old healthy participants in Zhongshan city.
Wuzhou cohort, Guangxi, China
30-69 years old healthy participants in Wuzhou city.
Interventions
Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.
Eligibility Criteria
30-69 years old healthy residences in Zhongshan City and Wuzhou City.
You may qualify if:
- Subject residents in Zhongshan or Wuzhou City;
- Subject has no medical record of prevalent cancer;
- Subject has psychical condition and well consciousness, and willingness to accept and cooperate with the study\'s follow-up procedures.
You may not qualify if:
- Subject has heavy cardiovascular, liver, or kidney disease;
- Subject has prevalent cancer.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sun Yat-sen Universitylead
- Wuzhou Red Cross Hospitalcollaborator
- Zhongshan People's Hospital, Guangdong, Chinacollaborator
Study Sites (2)
Zhongshan People's Hospital
Zhongshan, Guangdong, 528403, China
Wuzhou Red Cross Hospital
Wuzhou, Guangxi, 543002, China
Biospecimen
plasma or serum
MeSH Terms
Conditions
Central Study Contacts
Study Design
- Study Type
- observational
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
December 29, 2023
First Posted
January 12, 2024
Study Start
August 1, 2008
Primary Completion
December 31, 2024
Study Completion (Estimated)
December 31, 2030
Last Updated
January 12, 2024
Record last verified: 2024-01
Data Sharing
- IPD Sharing
- Will not share
In order to prioritize and uphold participant confidentiality and privacy, we have chosen not to provide Individual Participant Data (IPD). Our commitment is to ensure the highest level of protection for the sensitive information of our participants, aligning with ethical principles and privacy regulations. This decision is made to safeguard the well-being and privacy of the individuals involved in the study.